Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy

Launched by PEKING UNIVERSITY · May 6, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for patients with advanced gastric and esophageal cancer who are experiencing anorexia (loss of appetite) and cachexia (weight loss and muscle wasting). The study will compare a special form of megestrol acetate, which is a medication that can help increase appetite, combined with standard immunochemotherapy, to just the standard immunochemotherapy alone. The goal is to see if the combination treatment is more effective and safe for improving appetite and overall health in these patients.

To participate in this trial, individuals must be between 18 and 75 years old, have a certain level of physical ability (measured by a score from 0 to 2), and be expected to live for more than three months. They should also have good organ function. If someone is eligible and decides to join the study, they will be randomly assigned to receive either the combination treatment or the standard treatment. It's important to note that this trial is not yet recruiting participants, but it aims to help improve care for those facing these challenging symptoms related to their cancer.

Gender

ALL

Eligibility criteria

• • 1. Aged between 18 and 75 years old, regardless of gender；
• • 2. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2；
• • 3. The expected survival time is more than 3 months；
• • 4. Good organ function